Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Oncology Progress》 2018-02
Add to Favorite Get Latest Update

The role of ID3 gene in reversing cisplatin resistance of osteosarcoma and its mechanism

CHI Xiaofeng;JIANG Hong;YANG Dong;Department of Bone and Soft Tissue Tumor Surgery, Jilin Cancer Hospital;  
Objective To investigate the expression of ID3 gene in the reversal of cisplatin resistance in osteosarcoma and its effect on drug resistance, apoptosis and the expression of RhoE, P-gp and Caspase-3 in osteosarcoma cells.Method MTT assay was used to detect the growth of U-2 OS and U-2 OS/DDP cells, the expression of ID3 in U-2 OS and U-2 OS/DDP cells was detected by q RT-PCR and Western blot. Vectors with ID3 overexpression was applied to transfect U-2 OS/DDP cells, while blank liposome-transfected cells were utilized as control, all cells were cultured for 24 h,and then the expression of RhoE, P-gp and Caspase-3 protein in the cells were detected by Western blot; Reversal of drug resistance was determined by MTT; And apoptosis by flow cytometry. Result Drug resistance of resistant cells U-2 OS/DDP was significantly higher than that of U-2 OS cells, with lower expression of ID3 in the former than in the latter; the overexpression of ID3 gene could promote the apoptosis of U-2 OS/DDP cells; as ID3 overexpressed, the expression of P-gp was down-regulated while that of RhoE and Caspase-3 was up-regulated(P0.05). Conclusion The expression of ID3 gene in cisplatin-resistant cells U-2 OS/DDP cells is relatively low, but overexpression of ID3 gene could significantly reverse the drug resistance of U-2 OS/DDP cells and promote the apoptosis by regulating RhoE, P-gp and Caspase-3 protein, which is possibly correlated with the regulation of drug resistance.
【CateGory Index】: R738.1
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved